GAMMA Investing LLC Acquires 1,585 Shares of XOMA Royalty Corporation (NASDAQ:XOMA)

GAMMA Investing LLC raised its holdings in XOMA Royalty Corporation (NASDAQ:XOMA) by 1,063.8% in the first quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 1,734 shares of the biotechnology company’s stock after purchasing an additional 1,585 shares during the period. GAMMA Investing LLC’s holdings in XOMA Royalty were worth $35,000 at the end of the most recent quarter.

A number of other institutional investors have also recently bought and sold shares of XOMA. Woodline Partners LP lifted its holdings in shares of XOMA Royalty by 63.9% during the 4th quarter. Woodline Partners LP now owns 156,266 shares of the biotechnology company’s stock worth $4,107,000 after acquiring an additional 60,927 shares during the period. Eversept Partners LP lifted its holdings in shares of XOMA Royalty by 1.2% during the 4th quarter. Eversept Partners LP now owns 95,417 shares of the biotechnology company’s stock worth $2,508,000 after acquiring an additional 1,128 shares during the period. Northern Trust Corp lifted its holdings in shares of XOMA Royalty by 1.5% during the 4th quarter. Northern Trust Corp now owns 91,181 shares of the biotechnology company’s stock worth $2,396,000 after acquiring an additional 1,340 shares during the period. Charles Schwab Investment Management Inc. lifted its holdings in shares of XOMA Royalty by 5.8% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 23,113 shares of the biotechnology company’s stock worth $607,000 after acquiring an additional 1,276 shares during the period. Finally, Renaissance Technologies LLC lifted its holdings in shares of XOMA Royalty by 89.8% during the 4th quarter. Renaissance Technologies LLC now owns 16,100 shares of the biotechnology company’s stock worth $423,000 after acquiring an additional 7,619 shares during the period. Institutional investors own 95.92% of the company’s stock.

Analyst Ratings Changes

A number of brokerages have recently weighed in on XOMA. Wall Street Zen raised shares of XOMA Royalty from a “hold” rating to a “buy” rating in a report on Saturday, June 14th. Benchmark began coverage on shares of XOMA Royalty in a report on Thursday, April 17th. They set a “buy” rating and a $35.00 price target for the company. Finally, HC Wainwright reissued a “buy” rating and issued a $104.00 price objective on shares of XOMA Royalty in a research note on Wednesday, May 28th.

Insider Buying and Selling at XOMA Royalty

In other XOMA Royalty news, Director Joseph M. Limber purchased 17,935 shares of the company’s stock in a transaction dated Thursday, April 3rd. The stock was purchased at an average price of $25.24 per share, with a total value of $452,679.40. Following the completion of the purchase, the director now owns 16,524 shares of the company’s stock, valued at approximately $417,065.76. The trade was a -1,271.08% increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, major shareholder Bvf Partners L. P/Il sold 392,723 shares of the firm’s stock in a transaction on Friday, May 16th. The shares were sold at an average price of $27.10, for a total transaction of $10,642,793.30. Following the transaction, the insider now directly owns 1,267,545 shares of the company’s stock, valued at $34,350,469.50. The trade was a 23.65% decrease in their position. The disclosure for this sale can be found here. Insiders have purchased 25,178 shares of company stock worth $636,300 over the last quarter. Corporate insiders own 9.10% of the company’s stock.

XOMA Royalty Stock Performance

Shares of XOMA Royalty stock opened at $27.32 on Friday. XOMA Royalty Corporation has a fifty-two week low of $18.35 and a fifty-two week high of $35.00. The company has a debt-to-equity ratio of 1.18, a current ratio of 5.54 and a quick ratio of 5.54. The firm has a market capitalization of $327.02 million, a P/E ratio of -23.76 and a beta of 0.94. The company’s 50 day moving average price is $24.88 and its two-hundred day moving average price is $24.31.

XOMA Royalty (NASDAQ:XOMA) last issued its earnings results on Tuesday, May 13th. The biotechnology company reported $0.06 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.26) by $0.32. XOMA Royalty had a negative net margin of 13.04% and a negative return on equity of 12.43%. The firm had revenue of $15.91 million for the quarter, compared to analyst estimates of $6.75 million. On average, equities analysts forecast that XOMA Royalty Corporation will post -1.41 earnings per share for the current fiscal year.

XOMA Royalty Company Profile

XOMA Corporation operates as a biotech royalty aggregator in the United States and the Asia Pacific. It has a portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners; and acquires milestone and royalty revenue streams on late-stage clinical or commercial assets.